NEW YORK (GenomeWeb News) – Drug firm Summit and the Children's National Medical Center in Washington today announced a collaboration for the development of a proteomic assay to measure biomarkers in support of Summit's candidate drug for Duchenne Muscular Dystrophy (DMD).

Under the terms of the deal, Yetrib Hathout, a principal investigator at CNMC's Center for Genetic Medicine Research, will develop a mass spectrometry-based assay to measure levels of a protein called utrophin in DMD muscle that may prove useful in treating the disease.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.